1. Investigation into the anti-inflammatory mechanism of Pothos chinensis (Raf.) Merr. By regulating TLR4/MyD88/NF-κB pathway: Integrated network pharmacology, serum pharmacochemistry, and metabolomics.
- Author
-
Xiao, Guanlin, Yang, Minjuan, Zeng, Zhihao, Tang, Ruiyin, Jiang, Jieyi, Wu, Guangyin, Xie, Canhui, Jia, Dezheng, and Bi, Xiaoli
- Subjects
- *
TYROSINE metabolism , *PHENYLALANINE metabolism , *LIVER injuries , *ANTI-inflammatory agents , *NF-kappa B , *IN vitro studies , *COMPUTER-assisted molecular modeling , *CARRIER proteins , *LIQUID chromatography-mass spectrometry , *ARACHIDONIC acid , *PHARMACEUTICAL chemistry , *TOLL-like receptors , *CELLULAR signal transduction , *IN vivo studies , *PLANT extracts , *MEDICINAL plants , *MASS spectrometry , *LIQUID chromatography , *METABOLISM , *METABOLOMICS , *LIVER , *BIOMARKERS , *TUMOR necrosis factors , *INTERLEUKINS , *PHARMACODYNAMICS - Abstract
Inflammation is directly related to disease progression and contributes significantly to the global burden of disease. Pothos chinensis (Raf.) Merr. (PCM) is commonly used in Yao medicine in China to treat tumors, and orthopedic illnesses such as knee osteoarthritis, and rheumatic bone discomfort. PCM was found to have significant anti-inflammatory properties in previous studies. To explore the active compounds of PCM and their anti-inflammatory pharmacological mechanisms through an integrated strategy of serum pharmacochemistry, network pharmacology, and serum metabolomics. The qualitative and quantitative analyses of the chemical components of PCM were performed using UPLC-QTOF-MS/MS and UPLC, respectively, and the prototype components of PCM absorbed into the blood were analyzed. Based on the characterized absorbed into blood components, potential targets and signaling pathways of PCM anti-inflammatory were found using network pharmacology. Furthermore, metabolomics studies using UPLC-QTOF-MS/MS identified biomarkers and metabolic pathways related to the anti-inflammatory effects of PCM. Finally, the hypothesized mechanisms were verified by in vivo and in vitro experiments. Forty chemical components from PCM were identified for the first time, and seven of them were quantitatively analyzed, while five serum migratory prototype components were found. Network pharmacology KEGG enrichment analysis revealed that arachidonic acid metabolism, Tyrosine metabolism, TNF signaling pathway, NF-κB signaling pathway, and phenylalanine metabolism were the main signaling pathways of PCM anti-inflammatory. Pharmacodynamic results showed that PCM ameliorated liver injury and inflammatory cell infiltration and downregulated protein expression of IL-1β, NF-κB p65, and MyD88 in the liver. Metabolomics studies identified 53 different serum metabolites, mainly related to purine and pyrimidine metabolism, phenylalanine metabolism, primary bile acid biosynthesis, and glycerophospholipid metabolism. The comprehensive results demonstrated that the anti-inflammatory modulatory network of PCM was related to 5 metabolites, 3 metabolic pathways, 7 targets, and 4 active components of PCM. In addition, molecular docking identified the binding ability between the active ingredients and the core targets, and the anti-inflammatory efficacy of the active ingredients was verified by in vitro experiments. Our study demonstrated the anti-inflammatory effect of PCM, and these findings provide new insights into the active ingredients and metabolic mechanisms of PCM in anti-inflammation. [Display omitted] • The chemical composition of PCM was qualitatively and quantitatively analyzed. • PCM modulates LPS-induced inflammatory responses, which is closely related to the inhibition of TLR4/MyD88/NF-κB signaling. • The four active components in PCM were identified and the anti-inflammatory mechanism was preliminarily verified. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF